-
Je něco špatně v tomto záznamu ?
Clinical utility of a glycosylated fibronectin test (LumellaTM) for assessment of impending preeclampsia
GC. Di Renzo, M. Arduini, JL. Bartha, A. Froeliger, JS. Jorgensen, M. Kacerovsky, P. Stanirowski, M. Wielgos, L. Gao, MG. Gravett
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie
- MeSH
- biologické markery analýza MeSH
- dospělí MeSH
- fibronektiny * analýza MeSH
- gestační stáří MeSH
- glykované proteiny MeSH
- imunoanalýza metody MeSH
- lidé MeSH
- pilotní projekty MeSH
- point of care testing MeSH
- prediktivní hodnota testů MeSH
- preeklampsie * diagnóza MeSH
- prospektivní studie MeSH
- těhotenství MeSH
- vyšetření u lůžka MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
OBJECTIVE: Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality and morbidity, yet difficulties remain in the diagnosis of preeclampsia based on clinical parameters alone. The objective was to assess the performance of a hand-held point-of-care (POC) immunoassay in a clinical environment for glycosylated fibronectin (GlyFn) for the prediction of preeclampsia within 4 weeks of sampling. METHODS: Multinational European prospective observational pilot study of predominantly high-risk patients in the second half of pregnancy to assess a point-of-care immunoassay for GlyFn in predicting preeclampsia within 4 weeks of sampling. GlyFn was measured using a second generation hand held POC immunoassay. Results were considered normal for GlyFn concentrations of < 350 μg/mL, positive for GlyFn concentrations of 351-600 μg/mL, and high-positive for GlyFn concentrations > 600 μg/mL. RESULTS: Preeclampsia developed in 16 (19%) of 84 subjects and was associated with a shorter gestational age at delivery 35.3 weeks vs. 37.3 weeks for non-preeclamptics, n = 82; p = 0.001), a higher risk of fetal growth restriction (FGR; 31.2% vs. 10.3% for non-preeclamptics, p = 0.046), and an increased risk of preterm birth < 37 weeks gestation (83.3% vs. 33.3% for non-preeclamptics, (n = 78; p = 0.003). GlyFn positive or high positive was seen in 13/16 (81%) and in 35/68 (51.5%), yielding a sensitivity of 81%, a specificity of 49%, a positive predictive value of 27%, and a negative predictive value of 92%. GlyFn positive or high positive was also associated with preterm birth < 37 weeks in singleton pregnancy non-preeclamptic patients. Preterm birth occurred in 4.8% of those with normal GlyFn, in 26.7% with positive GlyFn, and in 50% of those with high GlyFn in singleton gestations without preeclampsia (p = 0.008). CONCLUSION: The ability to use this test in a POC format provides a method for practitioners to quickly determine risk for preeclampsia in their pregnant patients and offers an affordable alternative, as a single analyte to other diagnostic or screening tests that require laboratory-based testing or ultrasound equipment. Independent of preeclampsia, an elevated GlyFn was also correlated with preterm delivery and requires further study.
Biomedical Research Center University Hospital Hradec Králové Hradec Králové Czech Republic
Department of Obstetrics and Gynecology Bordeaux University Hospital Bordeaux France
Department of Obstetrics and Gynecology Hospital Most Ústí nad Labem Czech Republic
Department of Obstetrics and Gynecology Medical University of Warsaw Warsaw Poland
Obstetrics and Gynecology Department S Maria della Misericordia Hospital Perugia Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009255
- 003
- CZ-PrNML
- 005
- 20250429134927.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14767058.2025.2474674 $2 doi
- 035 __
- $a (PubMed)40051335
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Di Renzo, Gian Carlo $u PREIS School (The Permanent International and European School of Perinatal, Neonatal and Reproductive Medicine), Florence, Italy $u Department of Obstetrics, Gynecology and Perinatal Medicine, IM Sechenov First State University, Moscow, Russia
- 245 10
- $a Clinical utility of a glycosylated fibronectin test (LumellaTM) for assessment of impending preeclampsia / $c GC. Di Renzo, M. Arduini, JL. Bartha, A. Froeliger, JS. Jorgensen, M. Kacerovsky, P. Stanirowski, M. Wielgos, L. Gao, MG. Gravett
- 520 9_
- $a OBJECTIVE: Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality and morbidity, yet difficulties remain in the diagnosis of preeclampsia based on clinical parameters alone. The objective was to assess the performance of a hand-held point-of-care (POC) immunoassay in a clinical environment for glycosylated fibronectin (GlyFn) for the prediction of preeclampsia within 4 weeks of sampling. METHODS: Multinational European prospective observational pilot study of predominantly high-risk patients in the second half of pregnancy to assess a point-of-care immunoassay for GlyFn in predicting preeclampsia within 4 weeks of sampling. GlyFn was measured using a second generation hand held POC immunoassay. Results were considered normal for GlyFn concentrations of < 350 μg/mL, positive for GlyFn concentrations of 351-600 μg/mL, and high-positive for GlyFn concentrations > 600 μg/mL. RESULTS: Preeclampsia developed in 16 (19%) of 84 subjects and was associated with a shorter gestational age at delivery 35.3 weeks vs. 37.3 weeks for non-preeclamptics, n = 82; p = 0.001), a higher risk of fetal growth restriction (FGR; 31.2% vs. 10.3% for non-preeclamptics, p = 0.046), and an increased risk of preterm birth < 37 weeks gestation (83.3% vs. 33.3% for non-preeclamptics, (n = 78; p = 0.003). GlyFn positive or high positive was seen in 13/16 (81%) and in 35/68 (51.5%), yielding a sensitivity of 81%, a specificity of 49%, a positive predictive value of 27%, and a negative predictive value of 92%. GlyFn positive or high positive was also associated with preterm birth < 37 weeks in singleton pregnancy non-preeclamptic patients. Preterm birth occurred in 4.8% of those with normal GlyFn, in 26.7% with positive GlyFn, and in 50% of those with high GlyFn in singleton gestations without preeclampsia (p = 0.008). CONCLUSION: The ability to use this test in a POC format provides a method for practitioners to quickly determine risk for preeclampsia in their pregnant patients and offers an affordable alternative, as a single analyte to other diagnostic or screening tests that require laboratory-based testing or ultrasound equipment. Independent of preeclampsia, an elevated GlyFn was also correlated with preterm delivery and requires further study.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a preeklampsie $x diagnóza $7 D011225
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a těhotenství $7 D011247
- 650 12
- $a fibronektiny $x analýza $7 D005353
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a biologické markery $x analýza $7 D015415
- 650 _2
- $a imunoanalýza $x metody $7 D007118
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a vyšetření u lůžka $7 D019095
- 650 _2
- $a point of care testing $7 D000067716
- 650 _2
- $a gestační stáří $7 D005865
- 650 _2
- $a glykované proteiny $7 D000093844
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Arduini, Maurizio $u Obstetrics and Gynecology Department, S. Maria della Misericordia Hospital, Perugia, Italy
- 700 1_
- $a Bartha, Jose Luis $u Department of Obstetrics and Gynecology, University Hospital La Paz, Universidad Autónoma de Madrid, Spain
- 700 1_
- $a Froeliger, Alizee $u Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
- 700 1_
- $a Jorgensen, Jan Stener $u Department of Gynecology and Obstetrics, Research Unit of Gynecology and Obstetrics, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
- 700 1_
- $a Kacerovsky, Marian $u Biomedical Research Center, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Obstetrics and Gynecology, Hospital Most, Ústí nad Labem, Czech Republic
- 700 1_
- $a Stanirowski, Pawel $u Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000174457546
- 700 1_
- $a Wielgos, Miroslaw $u Department of Obstetrics and Perinatology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
- 700 1_
- $a Gao, Lina $u Biostatistics Shared Resources, Knight Cancer Institute, and Bioinformatics & Biostatistics Core, Oregon National Primate Research Center, Oregon Health & Science University
- 700 1_
- $a Gravett, Michael G $u Departments of Obstetrics and Gynecology and of Global Health, University of Washington, Seattle, WA, USA
- 773 0_
- $w MED00007048 $t Journal of maternal-fetal & neonatal medicine $x 1476-4954 $g Roč. 38, č. 1 (2025), s. 2474674
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40051335 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134922 $b ABA008
- 999 __
- $a ok $b bmc $g 2310942 $s 1246336
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 38 $c 1 $d 2474674 $e 20250307 $i 1476-4954 $m Journal of maternal-fetal & neonatal medicine $n J Matern Fetal Neonatal Med $x MED00007048
- LZP __
- $a Pubmed-20250415